Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665504 · ClinicalTrials.gov registry record
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
A clinical trial of Adenocarcinoma of Lung and Lung; Node, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT05665504: Recruiting study of Adenocarcinoma of Lung and Lung; Node, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05665504 is a study of Adenocarcinoma of Lung and Lung; Node that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 250 participants, above the 123-participant average among 5 other Adenocarcinoma of Lung trials with a reported enrollment target (103% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05665504, a study of Adenocarcinoma of Lung and Lung; Node, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.
Primary Outcome
Disease-free survival (DFS) is defined as the time from surgical resection and adjuvant chemotherapy to recurrence of tumor or death
Conditions Studied
Interventions
- DIAGNOSTIC_TEST DetermaRX
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2028-02 |
What NCT05665504 shows while recruiting
NCT05665504 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 123-participant average among 5 other Adenocarcinoma of Lung trials with a reported enrollment target (103% higher).
The record links to 2 conditions, with Adenocarcinoma of Lung appearing as the primary indexed condition, and to 1 intervention - of which DetermaRX is the first listed.
NCT05665504 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05665504 about?
NCT05665504 is a clinical study titled "Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer". This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identif...
What is the current status of trial NCT05665504?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2023-01-11. Estimated completion is 2028-02.
What conditions does trial NCT05665504 study?
This clinical trial studies the following conditions: Adenocarcinoma of Lung, Lung; Node.
What interventions are being tested in trial NCT05665504?
The interventions under investigation include: DetermaRX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05665504?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05665504 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
RECRUITING · Phase 2
-
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
RECRUITING · Phase 1
-
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
RECRUITING · Phase 2
-
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI